Hamit Bal

4PUBLICATIONS
105CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Feb 11, 2026
Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group.

Salih Tunbekici, Hamit Bal, Oguzcan Kınıkoglu

|Jan 28, 2026
Adjuvant Chemotherapy and Chemoradiotherapy in Gastric Cancer: Prognostic Determinants and Real-World Survival Outcomes.

Sedat Yildirim, Hatice Odabas, Seval Ay Ersoy

|Nov 17, 2025
Real-world comparison of doxorubicin-ifosfamide versus gemcitabine-docetaxel regimens in metastatic uterine leiomyosarcoma: a multicenter retrospective study.

Salih Tunbekici, Gokhan Sahin, Haydar Cagatay Yuksel

|May 27, 2024
The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy.

Sedat Yildirim, Akif Dogan, Goncagul Akdag

Pageof 1

Frequent Collaborators

3 joint publications

Salih Tunbekici

2 joint publications

Sedat Yildirim

2 joint publications

Nedim Turan

2 joint publications

Goncagul Akdag